دورية أكاديمية
Serum potassium and heart failure: association, causation, and clinical implications.
| العنوان: | Serum potassium and heart failure: association, causation, and clinical implications. |
|---|---|
| المؤلفون: | Sfairopoulos D; First Department of Cardiology, University of Ioannina Medical School, 45100, Ioannina, Greece., Arseniou A; First Department of Cardiology, University of Ioannina Medical School, 45100, Ioannina, Greece., Korantzopoulos P; First Department of Cardiology, University of Ioannina Medical School, 45100, Ioannina, Greece. p.korantzopoulos@yahoo.gr. |
| المصدر: | Heart failure reviews [Heart Fail Rev] 2021 May; Vol. 26 (3), pp. 479-486. Date of Electronic Publication: 2020 Oct 23. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Kluwer Academic Publishers Country of Publication: United States NLM ID: 9612481 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7322 (Electronic) Linking ISSN: 13824147 NLM ISO Abbreviation: Heart Fail Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Norwell, MA : Kluwer Academic Publishers, c1996- |
| مواضيع طبية MeSH: | Heart Failure*/drug therapy , Hyperkalemia* , Hypokalemia*/complications, Humans ; Potassium ; Renin-Angiotensin System |
| مستخلص: | Dyskalemia (hypo- and hyperkalemia) is a common clinical encounter in patients with heart failure (HF), linked to underlying pathophysiologic alterations, pharmacological treatments, and concomitant comorbidities. Both hypo- and hyperkalemia have been associated with a poor outcome in HF. However, it is not known if this association is causal. In order to investigate this relation, we implemented the Bradford Hill criteria for causation examining the available literature. Of note, hypokalemia and low-normal potassium levels (serum potassium < 4.0 mmol/L) appear to be associated with adverse clinical outcomes in HF in a cause-and-effect manner. Conversely, a cause-and-effect relationship between hyperkalemia (serum potassium > 5.0 mmol/L) and adverse clinical outcomes in HF appears unlikely. We also examined the benefits of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy uptitration in patients with HF and reduced ejection fraction. In fact, hyperkalemia often limits RAASi use, thereby negating or mitigating their clinical benefits. Finally, serum potassium levels in HF should be maintained within the range of 4.0-5.0 mmol/L, and although the correction of hyperkalemia does not appear to improve clinical outcomes per se, it may enable the optimal titration of RAASi, offering indirect clinical benefit. |
| References: | Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196. (PMID: 10.1016/S0140-6736(12)61729-2) Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137–1146. (PMID: 10.1136/hrt.2003.025270) Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:194–202. (PMID: 10.1001/jama.289.2.194) Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614–1619. (PMID: 10.1016/j.ehj.2004.06.038) Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A; EPICA Investigators. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002;4:531-539. Savarese G, Lund LH (2017) Global public health burden of heart failure. Card Fail Rev 3:7–11. (PMID: 10.15420/cfr.2016:25:2) Kilgore M, Patel HK, Kielhorn A, Maya JF, Sharma P (2017) Economic burden of hospitalizations of Medicare beneficiaries with heart failure. Risk Manag Healthc Policy 10:63–70. (PMID: 10.2147/RMHP.S130341) Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, et al; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016;133:e38-360. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975. Rosano GM, Spoletini I, Vitale C, Agewall S (2019) Hyperkalemia and renin-angiotensin-aldosterone system inhibitors dose therapy in heart failure with reduced ejection fraction. Card Fail Rev 5:130–132. (PMID: 10.15420/cfr.2019.8.2) Savarese G, Xu H, Trevisan M, Dahlström U, Rossignol P, Pitt B, Lund LH, Carrero JJ (2019) Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 7:65–76. (PMID: 10.1016/j.jchf.2018.10.003) Gumz ML, Rabinowitz L, Wingo CS (2015) An integrated view of potassium homeostasis. N Engl J Med 373:60–72. (PMID: 10.1056/NEJMra1313341) Aldahl M, Jensen AC, Davidsen L, Eriksen MA, Møller Hansen S, Nielsen BJ, Krogager ML, Køber L, Torp-Pedersen C, Søgaard P (2017) Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 38:2890–2896. (PMID: 10.1093/eurheartj/ehx460) CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295–1302. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658. Effect of metoprolol CR/XL in chronic heart failure (1999) Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007. (PMID: 10.1016/S0140-6736(99)04440-2) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:1169-1186. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 102:11–22. (PMID: 10.1007/s00392-012-0467-8) Krogager ML, Eggers-Kaas L, Aasbjerg K, Mortensen RN, Køber L, Gislason G, Torp-Pedersen C, Søgaard P (2015) Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur Heart J Cardiovasc Pharmacother 1:245–251. (PMID: 10.1093/ehjcvp/pvv026) Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, Bennett H, McEwan P (2019) Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail 6:280–290. (PMID: 10.1002/ehf2.12402) Hoss S, Elizur Y, Luria D, Keren A, Lotan C, Gotsman I (2016) Serum potassium levels and outcome in patients with chronic heart failure. Am J Cardiol 118:1868–1874. (PMID: 10.1016/j.amjcard.2016.08.078) Cooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ, Dahlström U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH. Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. Eur J Heart Fail 2020. doi: https://doi.org/10.1002/ejhf.1757 . Epub ahead of print. PMID: 32078214. Nishihara T, Tokitsu T, Sueta D, Takae M, Oike F, Fujisue K, Usuku H, Takashio S, Hanatani S, Kanazawa H, Arima Y, Sakamoto K, Izumiya Y, Yamabe H, Kaikita K, Yamamoto E, Tsujita K (2018) Serum potassium and cardiovascular events in heart failure with preserved left ventricular ejection fraction patients. Am J Hypertens 31:1098–1105. (PMID: 10.1093/ajh/hpy101) Palaka E, Grandy S, Darlington O, McEwan P, van Doornewaard A (2020) Associations between serum potassium and adverse clinical outcomes: a systematic literature review. Int J Clin Pract 74:e13421. (PMID: 10.1111/ijcp.13421) Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300. (PMID: 142838791898525) Fedak KM, Bernal A, Capshaw ZA, Gross S (2015) Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol 12:14. (PMID: 10.1186/s12982-015-0037-4) Tomaselli GF, Zipes DP (2004) What causes sudden death in heart failure? Circ Res 95:754–763. (PMID: 10.1161/01.RES.0000145047.14691.db) Skogestad J, Aronsen JM (2018) Hypokalemia-induced arrhythmias and heart failure: new insights and implications for therapy. Front Physiol 9:1500. (PMID: 10.3389/fphys.2018.01500) Weiss JN, Qu Z, Shivkumar K (2017) Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol 10:e004667. (PMID: 10.1161/CIRCEP.116.004667) Ferreira JP, Butler J, Rossignol P, Pitt B, Anker SD, Kosiborod M, Lund LH, Bakris GL, Weir MR, Zannad F (2020) Abnormalities of potassium in heart failure: JACC State-of-the-Art Review. J Am Coll Cardiol 75:2836–2850. (PMID: 10.1016/j.jacc.2020.04.021) Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-1848. Turgeon RD, Kolber MR, Loewen P, Ellis U, McCormack JP (2019) Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: systematic review and meta-analysis. PLoS One 14:e0212907. (PMID: 10.1371/journal.pone.0212907) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-907. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS (2018) Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 4:180–188. (PMID: 10.1093/ehjcvp/pvy015) Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J (2015) Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 21:S212-20. (PMID: 26619183) Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-1184. Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Rossignol P, Zannad F, Voors AA, van der Meer P (2018) Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur J Heart Fail 20:923–930. (PMID: 10.1002/ejhf.1079) Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014;7:573-579. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7:51–58. (PMID: 10.1161/CIRCHEARTFAILURE.113.000792) Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, Zannad F (2014) Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. Int J Cardiol 173:380–387. (PMID: 10.1016/j.ijcard.2014.02.034) Rosano GMC, Spoletini I, Agewall S (2019) Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate. Eur Heart J Suppl 21:A28–A33. (PMID: 10.1093/eurheartj/suy035) Zannad F, Ferreira JP, Pitt B (2019) Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. Eur Heart J 21:55–60. (PMID: 10.1093/eurheartj/suy034) Bielecka-Dabrowa A, Mikhailidis DP, Jones L, Rysz J, Aronow WS, Banach M (2012) The meaning of hypokalemia in heart failure. Int J Cardiol 158:12–17. (PMID: 10.1016/j.ijcard.2011.06.121) |
| فهرسة مساهمة: | Keywords: Heart failure; Hyperkalemia; Hypokalemia; Morbidity; Mortality; Potassium |
| المشرفين على المادة: | RWP5GA015D (Potassium) |
| تواريخ الأحداث: | Date Created: 20201024 Date Completed: 20211203 Latest Revision: 20211214 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/s10741-020-10039-9 |
| PMID: | 33098029 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-7322 |
|---|---|
| DOI: | 10.1007/s10741-020-10039-9 |